Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review

Conclusion 177Lu-PSMA systemic radiation therapy (SRT) is a well-tolerated and reliable treatment option against the management of the mCRPC stage of prostate carcinoma. Lacrimal glands and salivary glands are the major critical organs in 177Lu-PSMA SRT. Besides, tumors receive 3–6 times higher absorbed doses compared to organs at risk.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Review Articles Source Type: research